Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
Identifieur interne : 000261 ( Main/Exploration ); précédent : 000260; suivant : 000262Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
Auteurs : S Sohail Ahmed [Italie] ; Peter H. Schur [États-Unis] ; Noni E. Macdonald [Canada] ; Lawrence Steinman [États-Unis]Source :
- Journal of autoimmunity [ 1095-9157 ] ; 2014.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (), Adjuvants immunologiques (administration et posologie), Anticorps antiviraux (sang), Antigènes viraux (), Antigènes viraux (immunologie), Association médicamenteuse, Auto-immunité, Canada (épidémiologie), Europe (épidémiologie), Grippe humaine (), Grippe humaine (immunologie), Grippe humaine (épidémiologie), Humains, Narcolepsie (), Narcolepsie (physiopathologie), Pandémies (), Polysorbates (), Polysorbates (administration et posologie), Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H1N1 du virus de la grippe A (pathogénicité), Squalène (), Squalène (administration et posologie), Squalène (immunologie), Vaccination (effets indésirables), Vaccins antigrippaux (biosynthèse), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), alpha-Tocophérol (), alpha-Tocophérol (administration et posologie), alpha-Tocophérol (immunologie).
- MESH :
- administration et posologie : Adjuvants immunologiques, Polysorbates, Squalène, alpha-Tocophérol.
- biosynthèse : Vaccins antigrippaux.
- effets indésirables : Vaccination, Vaccins antigrippaux.
- immunologie : Antigènes viraux, Grippe humaine, Sous-type H1N1 du virus de la grippe A, Squalène, Vaccins antigrippaux, alpha-Tocophérol.
- pathogénicité : Sous-type H1N1 du virus de la grippe A.
- physiopathologie : Narcolepsie.
- sang : Anticorps antiviraux.
- épidémiologie : Canada, Europe, Grippe humaine.
- Adjuvants immunologiques, Antigènes viraux, Association médicamenteuse, Auto-immunité, Grippe humaine, Humains, Narcolepsie, Pandémies, Polysorbates, Squalène, alpha-Tocophérol.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adjuvants, Immunologic (chemistry), Antibodies, Viral (blood), Antigens, Viral (chemistry), Antigens, Viral (immunology), Autoimmunity, Canada (epidemiology), Drug Combinations, Europe (epidemiology), Humans, Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H1N1 Subtype (pathogenicity), Influenza Vaccines (adverse effects), Influenza Vaccines (biosynthesis), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (immunology), Influenza, Human (prevention & control), Narcolepsy (chemically induced), Narcolepsy (physiopathology), Pandemics (prevention & control), Polysorbates (administration & dosage), Polysorbates (chemistry), Squalene (administration & dosage), Squalene (chemistry), Squalene (immunology), Vaccination (adverse effects), alpha-Tocopherol (administration & dosage), alpha-Tocopherol (chemistry), alpha-Tocopherol (immunology).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Polysorbates, Squalene, alpha-Tocopherol.
- chemical , adverse effects : Influenza Vaccines.
- chemical , biosynthesis : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , chemistry : Adjuvants, Immunologic, Antigens, Viral, Polysorbates, Squalene, alpha-Tocopherol.
- chemical , immunology : Antigens, Viral, Influenza Vaccines, Squalene, alpha-Tocopherol.
- geographic , epidemiology : Canada, Europe.
- adverse effects : Vaccination.
- chemically induced : Narcolepsy.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza, Human.
- pathogenicity : Influenza A Virus, H1N1 Subtype.
- physiopathology : Narcolepsy.
- prevention & control : Influenza, Human, Pandemics.
- Autoimmunity, Drug Combinations, Humans.
Abstract
The vaccine safety surveillance system effectively detected a very rare adverse event, narcolepsy, in subjects receiving AS03-adjuvanted A(H1N1) pandemic vaccine made using the European inactivation/purification protocol. The reports of increased cases of narcolepsy in non-vaccinated subjects infected with wild A(H1N1) pandemic influenza virus suggest a role for the viral antigen(s) in disease development. However, additional investigations are needed to better understand what factor(s) in wild influenza infection trigger(s) narcolepsy in susceptible hosts. An estimated 31 million doses of European AS03-adjuvanted A(H1N1) pandemic vaccine were used in more than 47 countries. The Canadian AS03-adjuvanted A(H1N1) pandemic vaccine was used with high coverage in Canada where an estimated 12 million doses were administered. As no similar narcolepsy association has been reported to date with the AS03-adjuvanted A(H1N1) pandemic vaccine made using the Canadian inactivation/purification protocol, this suggests that the AS03 adjuvant alone may not be responsible for the narcolepsy association. To date, no narcolepsy association has been reported with the MF59®-adjuvanted A(H1N1) pandemic vaccine. This review article provides a brief background on narcolepsy, outlines the different types of vaccine preparations including the ones for influenza, reviews the accumulated evidence for the safety of adjuvants, and explores the association between autoimmune diseases and natural infections. It concludes by assimilating the historical observations and recent clinical studies to formulate a feasible hypothesis on why vaccine-associated narcolepsy may not be solely linked to the AS03 adjuvant but more likely be linked to how the specific influenza antigen component of the European AS03-adjuvanted pandemic vaccine was prepared. Careful and long-term epidemiological studies of subjects who developed narcolepsy in association with AS03-adjuvanted A(H1N1) pandemic vaccine prepared with the European inactivation/purification protocol are needed.
DOI: 10.1016/j.jaut.2014.01.033
PubMed: 24559657
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.</title><author><name sortKey="Ahmed, S Sohail" sort="Ahmed, S Sohail" uniqKey="Ahmed S" first="S Sohail" last="Ahmed">S Sohail Ahmed</name><affiliation wicri:level="1"><nlm:affiliation>Global Clinical Sciences, Vaccines Research, Novartis Vaccines Srl, via, Fiorentina 1, Siena 53100, Italy. Electronic address: sohail.ahmed@novartis.com.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Global Clinical Sciences, Vaccines Research, Novartis Vaccines Srl, via, Fiorentina 1, Siena 53100</wicri:regionArea><wicri:noRegion>Siena 53100</wicri:noRegion></affiliation></author><author><name sortKey="Schur, Peter H" sort="Schur, Peter H" uniqKey="Schur P" first="Peter H" last="Schur">Peter H. Schur</name><affiliation wicri:level="2"><nlm:affiliation>Harvard Medical School, Division of Rheumatology, Brigham and Women's, Hospital, 45 Francis Street, Boston, MA 02115, USA. Electronic address: pschur@partners.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harvard Medical School, Division of Rheumatology, Brigham and Women's, Hospital, 45 Francis Street, Boston, MA 02115</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Macdonald, Noni E" sort="Macdonald, Noni E" uniqKey="Macdonald N" first="Noni E" last="Macdonald">Noni E. Macdonald</name><affiliation wicri:level="1"><nlm:affiliation>Dalhousie University, Division Pediatric Infectious Diseases, IWK Health Center, 5850/5980 University Avenue, PO Box 9700, Halifax, Nova Scotia B3K 6R8, Canada. Electronic address: noni.macdonald@dal.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Dalhousie University, Division Pediatric Infectious Diseases, IWK Health Center, 5850/5980 University Avenue, PO Box 9700, Halifax, Nova Scotia B3K 6R8</wicri:regionArea><wicri:noRegion>Nova Scotia B3K 6R8</wicri:noRegion></affiliation></author><author><name sortKey="Steinman, Lawrence" sort="Steinman, Lawrence" uniqKey="Steinman L" first="Lawrence" last="Steinman">Lawrence Steinman</name><affiliation wicri:level="2"><nlm:affiliation>Beckman Center for Molecular Medicine, B002, 279 Campus Drive, Stanford University, Stanford, CA 94305, USA. Electronic address: steinman@stanford.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Beckman Center for Molecular Medicine, B002, 279 Campus Drive, Stanford University, Stanford, CA 94305</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24559657</idno><idno type="pmid">24559657</idno><idno type="doi">10.1016/j.jaut.2014.01.033</idno><idno type="wicri:Area/Main/Corpus">000284</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000284</idno><idno type="wicri:Area/Main/Curation">000284</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000284</idno><idno type="wicri:Area/Main/Exploration">000284</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.</title><author><name sortKey="Ahmed, S Sohail" sort="Ahmed, S Sohail" uniqKey="Ahmed S" first="S Sohail" last="Ahmed">S Sohail Ahmed</name><affiliation wicri:level="1"><nlm:affiliation>Global Clinical Sciences, Vaccines Research, Novartis Vaccines Srl, via, Fiorentina 1, Siena 53100, Italy. Electronic address: sohail.ahmed@novartis.com.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Global Clinical Sciences, Vaccines Research, Novartis Vaccines Srl, via, Fiorentina 1, Siena 53100</wicri:regionArea><wicri:noRegion>Siena 53100</wicri:noRegion></affiliation></author><author><name sortKey="Schur, Peter H" sort="Schur, Peter H" uniqKey="Schur P" first="Peter H" last="Schur">Peter H. Schur</name><affiliation wicri:level="2"><nlm:affiliation>Harvard Medical School, Division of Rheumatology, Brigham and Women's, Hospital, 45 Francis Street, Boston, MA 02115, USA. Electronic address: pschur@partners.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harvard Medical School, Division of Rheumatology, Brigham and Women's, Hospital, 45 Francis Street, Boston, MA 02115</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Macdonald, Noni E" sort="Macdonald, Noni E" uniqKey="Macdonald N" first="Noni E" last="Macdonald">Noni E. Macdonald</name><affiliation wicri:level="1"><nlm:affiliation>Dalhousie University, Division Pediatric Infectious Diseases, IWK Health Center, 5850/5980 University Avenue, PO Box 9700, Halifax, Nova Scotia B3K 6R8, Canada. Electronic address: noni.macdonald@dal.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Dalhousie University, Division Pediatric Infectious Diseases, IWK Health Center, 5850/5980 University Avenue, PO Box 9700, Halifax, Nova Scotia B3K 6R8</wicri:regionArea><wicri:noRegion>Nova Scotia B3K 6R8</wicri:noRegion></affiliation></author><author><name sortKey="Steinman, Lawrence" sort="Steinman, Lawrence" uniqKey="Steinman L" first="Lawrence" last="Steinman">Lawrence Steinman</name><affiliation wicri:level="2"><nlm:affiliation>Beckman Center for Molecular Medicine, B002, 279 Campus Drive, Stanford University, Stanford, CA 94305, USA. Electronic address: steinman@stanford.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Beckman Center for Molecular Medicine, B002, 279 Campus Drive, Stanford University, Stanford, CA 94305</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><series><title level="j">Journal of autoimmunity</title><idno type="eISSN">1095-9157</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Adjuvants, Immunologic (chemistry)</term><term>Antibodies, Viral (blood)</term><term>Antigens, Viral (chemistry)</term><term>Antigens, Viral (immunology)</term><term>Autoimmunity</term><term>Canada (epidemiology)</term><term>Drug Combinations</term><term>Europe (epidemiology)</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza A Virus, H1N1 Subtype (pathogenicity)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (biosynthesis)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Narcolepsy (chemically induced)</term><term>Narcolepsy (physiopathology)</term><term>Pandemics (prevention & control)</term><term>Polysorbates (administration & dosage)</term><term>Polysorbates (chemistry)</term><term>Squalene (administration & dosage)</term><term>Squalene (chemistry)</term><term>Squalene (immunology)</term><term>Vaccination (adverse effects)</term><term>alpha-Tocopherol (administration & dosage)</term><term>alpha-Tocopherol (chemistry)</term><term>alpha-Tocopherol (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques ()</term><term>Adjuvants immunologiques (administration et posologie)</term><term>Anticorps antiviraux (sang)</term><term>Antigènes viraux ()</term><term>Antigènes viraux (immunologie)</term><term>Association médicamenteuse</term><term>Auto-immunité</term><term>Canada (épidémiologie)</term><term>Europe (épidémiologie)</term><term>Grippe humaine ()</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Narcolepsie ()</term><term>Narcolepsie (physiopathologie)</term><term>Pandémies ()</term><term>Polysorbates ()</term><term>Polysorbates (administration et posologie)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Sous-type H1N1 du virus de la grippe A (pathogénicité)</term><term>Squalène ()</term><term>Squalène (administration et posologie)</term><term>Squalène (immunologie)</term><term>Vaccination (effets indésirables)</term><term>Vaccins antigrippaux (biosynthèse)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (immunologie)</term><term>alpha-Tocophérol ()</term><term>alpha-Tocophérol (administration et posologie)</term><term>alpha-Tocophérol (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Polysorbates</term><term>Squalene</term><term>alpha-Tocopherol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Antigens, Viral</term><term>Polysorbates</term><term>Squalene</term><term>alpha-Tocopherol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term><term>Influenza Vaccines</term><term>Squalene</term><term>alpha-Tocopherol</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term><term>Europe</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Polysorbates</term><term>Squalène</term><term>alpha-Tocophérol</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Narcolepsy</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes viraux</term><term>Grippe humaine</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Squalène</term><term>Vaccins antigrippaux</term><term>alpha-Tocophérol</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Narcolepsie</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Narcolepsy</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term><term>Europe</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Autoimmunity</term><term>Drug Combinations</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Antigènes viraux</term><term>Association médicamenteuse</term><term>Auto-immunité</term><term>Grippe humaine</term><term>Humains</term><term>Narcolepsie</term><term>Pandémies</term><term>Polysorbates</term><term>Squalène</term><term>alpha-Tocophérol</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The vaccine safety surveillance system effectively detected a very rare adverse event, narcolepsy, in subjects receiving AS03-adjuvanted A(H1N1) pandemic vaccine made using the European inactivation/purification protocol. The reports of increased cases of narcolepsy in non-vaccinated subjects infected with wild A(H1N1) pandemic influenza virus suggest a role for the viral antigen(s) in disease development. However, additional investigations are needed to better understand what factor(s) in wild influenza infection trigger(s) narcolepsy in susceptible hosts. An estimated 31 million doses of European AS03-adjuvanted A(H1N1) pandemic vaccine were used in more than 47 countries. The Canadian AS03-adjuvanted A(H1N1) pandemic vaccine was used with high coverage in Canada where an estimated 12 million doses were administered. As no similar narcolepsy association has been reported to date with the AS03-adjuvanted A(H1N1) pandemic vaccine made using the Canadian inactivation/purification protocol, this suggests that the AS03 adjuvant alone may not be responsible for the narcolepsy association. To date, no narcolepsy association has been reported with the MF59®-adjuvanted A(H1N1) pandemic vaccine. This review article provides a brief background on narcolepsy, outlines the different types of vaccine preparations including the ones for influenza, reviews the accumulated evidence for the safety of adjuvants, and explores the association between autoimmune diseases and natural infections. It concludes by assimilating the historical observations and recent clinical studies to formulate a feasible hypothesis on why vaccine-associated narcolepsy may not be solely linked to the AS03 adjuvant but more likely be linked to how the specific influenza antigen component of the European AS03-adjuvanted pandemic vaccine was prepared. Careful and long-term epidemiological studies of subjects who developed narcolepsy in association with AS03-adjuvanted A(H1N1) pandemic vaccine prepared with the European inactivation/purification protocol are needed. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24559657</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2014</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9157</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of autoimmunity</Title><ISOAbbreviation>J. Autoimmun.</ISOAbbreviation></Journal><ArticleTitle>Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.</ArticleTitle><Pagination><MedlinePgn>1-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaut.2014.01.033</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-8411(14)00038-9</ELocationID><Abstract><AbstractText>The vaccine safety surveillance system effectively detected a very rare adverse event, narcolepsy, in subjects receiving AS03-adjuvanted A(H1N1) pandemic vaccine made using the European inactivation/purification protocol. The reports of increased cases of narcolepsy in non-vaccinated subjects infected with wild A(H1N1) pandemic influenza virus suggest a role for the viral antigen(s) in disease development. However, additional investigations are needed to better understand what factor(s) in wild influenza infection trigger(s) narcolepsy in susceptible hosts. An estimated 31 million doses of European AS03-adjuvanted A(H1N1) pandemic vaccine were used in more than 47 countries. The Canadian AS03-adjuvanted A(H1N1) pandemic vaccine was used with high coverage in Canada where an estimated 12 million doses were administered. As no similar narcolepsy association has been reported to date with the AS03-adjuvanted A(H1N1) pandemic vaccine made using the Canadian inactivation/purification protocol, this suggests that the AS03 adjuvant alone may not be responsible for the narcolepsy association. To date, no narcolepsy association has been reported with the MF59®-adjuvanted A(H1N1) pandemic vaccine. This review article provides a brief background on narcolepsy, outlines the different types of vaccine preparations including the ones for influenza, reviews the accumulated evidence for the safety of adjuvants, and explores the association between autoimmune diseases and natural infections. It concludes by assimilating the historical observations and recent clinical studies to formulate a feasible hypothesis on why vaccine-associated narcolepsy may not be solely linked to the AS03 adjuvant but more likely be linked to how the specific influenza antigen component of the European AS03-adjuvanted pandemic vaccine was prepared. Careful and long-term epidemiological studies of subjects who developed narcolepsy in association with AS03-adjuvanted A(H1N1) pandemic vaccine prepared with the European inactivation/purification protocol are needed. </AbstractText><CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>S Sohail</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Global Clinical Sciences, Vaccines Research, Novartis Vaccines Srl, via, Fiorentina 1, Siena 53100, Italy. Electronic address: sohail.ahmed@novartis.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schur</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Division of Rheumatology, Brigham and Women's, Hospital, 45 Francis Street, Boston, MA 02115, USA. Electronic address: pschur@partners.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacDonald</LastName><ForeName>Noni E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Dalhousie University, Division Pediatric Infectious Diseases, IWK Health Center, 5850/5980 University Avenue, PO Box 9700, Halifax, Nova Scotia B3K 6R8, Canada. Electronic address: noni.macdonald@dal.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinman</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Beckman Center for Molecular Medicine, B002, 279 Campus Drive, Stanford University, Stanford, CA 94305, USA. Electronic address: steinman@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Autoimmun</MedlineTA><NlmUniqueID>8812164</NlmUniqueID><ISSNLinking>0896-8411</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C550253">ASO3B adjuvant</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089950">MF59 oil emulsion</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance></Chemical><Chemical><RegistryNumber>7QWM220FJH</RegistryNumber><NameOfSubstance UI="D013185">Squalene</NameOfSubstance></Chemical><Chemical><RegistryNumber>H4N855PNZ1</RegistryNumber><NameOfSubstance UI="D024502">alpha-Tocopherol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="Y">Autoimmunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009290" MajorTopicYN="N">Narcolepsy</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024502" MajorTopicYN="N">alpha-Tocopherol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adjuvants</Keyword><Keyword MajorTopicYN="N">Autoimmune disease</Keyword><Keyword MajorTopicYN="N">H1N1 infection</Keyword><Keyword MajorTopicYN="N">Molecular mimicry</Keyword><Keyword MajorTopicYN="N">Narcolepsy</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>12</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>01</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>01</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24559657</ArticleId><ArticleId IdType="pii">S0896-8411(14)00038-9</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2014.01.033</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>Italie</li><li>États-Unis</li></country><region><li>Californie</li><li>Massachusetts</li></region></list><tree><country name="Italie"><noRegion><name sortKey="Ahmed, S Sohail" sort="Ahmed, S Sohail" uniqKey="Ahmed S" first="S Sohail" last="Ahmed">S Sohail Ahmed</name></noRegion></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="Schur, Peter H" sort="Schur, Peter H" uniqKey="Schur P" first="Peter H" last="Schur">Peter H. Schur</name></region><name sortKey="Steinman, Lawrence" sort="Steinman, Lawrence" uniqKey="Steinman L" first="Lawrence" last="Steinman">Lawrence Steinman</name></country><country name="Canada"><noRegion><name sortKey="Macdonald, Noni E" sort="Macdonald, Noni E" uniqKey="Macdonald N" first="Noni E" last="Macdonald">Noni E. Macdonald</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000261 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000261 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24559657
|texte= Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24559657" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |